Physician profile
Albert DO
NPI 1942575154
$20,326.82
in general payments reported to CMS, 2019-2025
7 companies · $16K in 2025
The $16K reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2024: $3,625 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $1,581 · Travel and Lodging: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,448.50 |
| Food and Beverage | $1,580.79 |
| Travel and Lodging | $1,425.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $19,091.41 | 2024-2025 | Rezdiffra |
| Celgene Corporation | $872.20 | 2019 | |
| Mallinckrodt Hospital Products INC. | $149.72 | 2024 | Terlivaz |
| Gilead Sciences, INC. | $122.31 | 2025 | Livdelzi |
| Ipsen Biopharmaceuticals, INC | $72.18 | 2025 | Iqirvo |
| Intuitive Surgical, INC. | $19.00 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.